MedMira Secures Approval for New HIV and Syphilis Self-Testing Trials

MedMira Inc. has announced the receipt of Investigational Testing Authorizations from Health Canada. This clearance allows MedMira to initiate clinical trials for new label claims on its Multiplo® TP/HIV rapid test, which has already gained Health Canada's approval. The trials focus on self-testing and non-professional use, offering expanded access to HIV and syphilis testing across Canada.

These trials arise in response to surging rates of syphilis and HIV, especially notable in Canada's Prairie regions. They will be conducted by REACH Nexus at St. Michael's Hospital, funded by the Canadian Institutes of Health Research. The tests, easy to use and delivering immediate results, are designed to break down barriers to accessible healthcare.

Current data reveals a steep rise in these infections, urging necessary interventions. MedMira's new testing solutions aim to aid over 8,000 Canadians unaware of their HIV status. The trials involve partnerships with healthcare providers and community organizations.